1. Scrip

Debiopharm files new Trelstar formulation in US

 
• By Malini Guha

[C#199100420:Debiopharm] has filed an NDA with the US FDAfor its six-month sustained-release formulation of Trelstar (triptorelin pamoate) for the treatment of locally advanced or metastatic hormone-dependent prostate cancer. If approved, Trelstar will be marketed in the US by [C#198601285:Watson] Pharmaceuticals.

Debiopharm has filed an NDA with the US FDAfor its six-month sustained-release formulation of Trelstar (triptorelin pamoate) for the treatment of locally advanced or metastatic hormone-dependent prostate cancer. If approved, Trelstar will be marketed in the US by Watson Pharmaceuticals.

In September, Ipsen filed the drug under the trade name Decapeptyl in Europe (ScripOnline, October 3rd, 2008).

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

More from Therapeutic Category

UCB Follows Fellow European Pharmas With Major US Investment

 
• By Kevin Grogan

The Belgian drugmaker is boosting its biologics capacity over the pond.

In Brief: Starton Moves Low-Dose Lenalidomide To Phase IIa For Multiple Myeloma

 
• By Sushmita Panda

Study to add to safety and tolerability data for infused formulation and may help identify optimal dose for future pivotal trial.

Lilly Looks For Muscle-Sparing Candidates In Pact With Juvena

 
• By Joseph Haas

Deal Snapshot: Including its internal efforts with bimagrumab, Lilly has been seeking a muscle-sparing therapy to complement GLP-1 obesity drugs, such as Zepbound.